Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QX-4533 placebo, an oral investigational drug, administered as oral tablets in single or repeated dose escalation schedules for moderate-to-severe atopic dermatitis patients and healthy volunteers”In the company’s words, NCT07800104 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis
- Main trialPhase 1
- “The primary purpose of this study is to evaluate the safety and tolerability of QX-4533 following oral administration of single and multiple ascending doses in healthy participants.”In the company’s words, NCT07678463 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
Coming up2
- 25 DecPhase 1 trial completes · ClinicalTrials.gov
- 14 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 25 Dec 2026 | A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants | |
| Phase 1Recruiting | 14 Apr 2027 | Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026